title: Trisomy 21 as the sole acquired karyotypic abnormality in biphenotypic acute leukemia.
authors.affiliation: Department of Internal Medicine (I), Osaka Medical College, Osaka, Japan. in1230@poh.osaka-med.ac.jp
authors.forename: Satoko
authors.initials: S
authors.lastname: Oka
authors.forename: Taiji
authors.initials: T
authors.lastname: Yokote
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Akioka
authors.forename: Satoshi
authors.initials: S
authors.lastname: Hara
authors.forename: Kichinosuke
authors.initials: K
authors.lastname: Kobayashi
authors.forename: Yuji
authors.initials: Y
authors.lastname: Hirata
authors.forename: Nobuya
authors.initials: N
authors.lastname: Hiraoka
authors.forename: Motomu
authors.initials: M
authors.lastname: Tsuji
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Hanafusa
mesh_terms: D000208:Acute Disease / Q000145:classification / Q000628:therapy; D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002869:Chromosome Aberrations; D003520:Cyclophosphamide / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004314:Down Syndrome / Q000097:blood* / Q000473:pathology*; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D007938:Leukemia / Q000145:classification / Q000235:genetics* / Q000628:therapy; D008297:Male; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use
chemical_list: D014750:Vincristine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide